Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bishop, A. E.
Right arrow Articles by Bloom, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bishop, A. E.
Right arrow Articles by Bloom, S. R.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 30, Issue 2 122-126, Copyright © 1981 by American Diabetes Association


ARTICLES

Decrease of pancreatic somatostatin in neonatal nesidioblastosis

AE Bishop, JM Polak, PG Chesa, CM Timson, MG Bryant and SR Bloom

The inappropriate insulin release that is characteristic of severe neonatal hypoglycemia and nesidioblastosis was thought to be principally due to a marked proliferation of B-cells. A possible deficiency of somatostatin, one of the factors controlling insulin release, has only recently been considered. We report have a significant decrease of pancreatic somatostatin cells and somatostatin content in nesidioblastosis, as compared with appropriate controls. Pancreatic tissue from five babies with severe hypoglycemia, hyperinsulinemia, and nesidioblastosis was examined for insulin, somatostatin, and glucagon by immunocytochemistry and radioimmunoassay. There was a variable insulin cell hyperplasia among the nesidioblastotic specimens but no significant difference from controls was detected. In contrast, there was a consistent and highly significant (P less than 0.02) decrease (of more than 50%) of somatostatin cells (controls, 1.29 +/- 0.22%; nesidioblastosis, 0.53 +/- 0.14%, mean +/- SEM). Similarly, there was no significant alteration in insulin content, although a slight increase was found in non-microadenomatous areas of the diseased pancreata (controls, 42.3 +/- 4.1; nesidioblastosis, 58.6 +/- 9.4 nmol/g wet weight of tissue, mean +/- SEM). However, somatostatin content was almost 60% below control values (controls, 0.365 +/- 0.038; nesidioblastosis, 0.16 +/- 0.039 nmol/g), a statistically significant difference (P less than 0.01). Thus, a marked reduction in the content of somatostatin was present in the pancreata of these infants with nesidioblastosis, resulting in a distinct alteration of the normal pancreatic hormone balance.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Arch. Dis. Child. Fetal Neonatal Ed.Home page
J Rahier, Y Guiot, and C Sempoux
Persistent hyperinsulinaemic hypoglycaemia of infancy: a heterogeneous syndrome unrelated to nesidioblastosis
Arch. Dis. Child. Fetal Neonatal Ed., March 1, 2000; 82(2): 108F - 112.
[Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
C. Sempoux, Y. Guiot, A. Lefevre, C. Nihoul-Fékété, F. Jaubert, J-M. Saudubray, and J. Rahier
Neonatal Hyperinsulinemic Hypoglycemia: Heterogeneity of the Syndrome and Keys for Differential Diagnosis
J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1455 - 1461.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1981 by the American Diabetes Association.